Register
Login:
Share:
Email Facebook Twitter

Add Gw Pharmaceuticals to quick picks

Gw Pharmaceuticals Share Price (GWP)



Share Price Information for Gw Pharmaceuticals (GWP)


Share Price: 427.00Bid: 426.00Ask: 427.50Change: 4.25 (+1.01%)Riser - Gw Pharm.
Spread: 1.50Spread as %: 0.35%Open: 426.00High: 433.50Low: 416.00Yesterday’s Close: 422.75
InfoGet Live Streaming Prices for GWP - Click here to start your 30 day FREE trial today.


Gw Pharmaceuticals Plc Ord 0.1P

Gw Pharmaceuticals is listed in the FTSE AIM 100, FTSE AIM UK 50, FTSE AIM All-Share
Gw Pharmaceuticals is part of the Pharmaceuticals & Biotechnology sector




Intraday Gw Pharmaceuticals Share Chart


Intraday Gw Pharmaceuticals Share Price Chart


Share Price SpacerPrice
427.00

Share Price SpacerBid
426.00

Share Price SpacerAsk
427.50

Share Price SpacerChange
1.01%4.25

Share Price SpacerVolume
95,366

Share Price SpacerOpen
426.00

Share Price SpacerHigh
433.50

Share Price SpacerLow
416.00

Share Price SpacerClose
422.75

Share Price SpacerCurrency
GBX

3 Month Gw Pharmaceuticals Share Graph


3 Month Gw Pharmaceuticals Share Price Graph


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 234.33m £1,000.59m 3,000

52 Week High 541.00 52 Week High Date 1-JUL-2014
52 Week Low 49.25 52 Week Low Date 26-JUL-2013

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
223 49,532 45,700 -142.333 -3.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

24-Jul-14
17:04:00
426.71
547
Sell* 
426.00
427.50
2,334
Trade Type:
Ordinary

24-Jul-14
17:03:42
426.718
2,727
Sell* 
426.00
427.50
11.64k
Trade Type:
Ordinary

24-Jul-14
16:35:05
427.00
3,219
Buy* 
426.00
427.00
13.75k
UT 
Trade Type:
Uncrossing Trade


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Gw Pharmaceuticals trades >>

Directors Deals for Gw Pharmaceuticals (GWP)
Trade DateActionNotifierPriceCurrencyAmountHolding
26-Nov-13Transfer To
Trade Notifier Information for GW Pharmaceuticals
Justin Gover held the position of Managing Director at GW Pharmaceuticals at the time of this trade.
 Justin Gover
0500,0003483368
30-Sep-13Notification of Holding
Trade Notifier Information for GW Pharmaceuticals
Christopher John Tovey held the position of Chief Operating Officer at GW Pharmaceuticals at the time of this trade.
 Christopher John Tovey
000
10-Jun-13Buy
Trade Notifier Information for GW Pharmaceuticals
Christopher John Tovey held the position of Chief Operating Officer at GW Pharmaceuticals at the time of this trade.
 Christopher John Tovey
0.1GBX7,50012500
View more Gw Pharmaceuticals directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 09:54
KUSHTY
TIME TO BUY NOW AND HOLD
418.75
No Opinion

I FOUND THIS SO I GUESS ITS TIME TO BUY BUY BUY N HOLD IT WAS PUBLISHED ON 21/7/14....... New Year wait for cannabis Published 21/07/2014 People with multiple sclerosis are expected to wait until early next year before the cannabis-based medicine, which can relieve symptoms, becomes available. Regulations have been signed to pave the way to enable authorised cannabis-based medicinal products, including Sativex, to be legally prescribed to patients. However, it will have to go through assessment at the National Centre for Pharmcoeconomics to determine if it will be available on State drugs schemes. No cost for the medication is available here yet. There are around 8,000 people in Ireland with multiple sclerosis and Sativex could bring relief to a significant number of them. Beaumont Hospital neurologist, Dr Orla Hardiman, said the assessment could take several months and it is likely to be next year before it is finalised. The drug can ease symptoms of spasticity, where muscles become stiff and resistant to movement. It may be prescribed where other treatments have failed. Only doctors specialising in multiple sclerosis, such as neurologists or pain consultants, are expected to be allowed to prescribe the drug, which is an oral spray. It can only be prescribed to those who have found that other drugs did not bring relief, or who experienced side effects when taking them. Sativex is already available in several other European countries. MS Ireland, which campaigned for its availability, said that, in 2010, an Irish study carried out by the University of Limerick found that 68pc of people with the disease reported some degree of spasticity. If left untreated, spasticity can lead to pressure sores, falls and serious fatigue. © Independent.ie
Wed 18:21
kingskin
RE: Jim Crammers Lighting Round.
422.75
No Opinion

do you really want him to hype it up to crash again?? we dont need his bloody advice. we need gw to get on the cancer train http://www.thestreet.com/story/12783508/1/puma-shares-soar-when-wall-street-misplays-expectation-game.html?puc=yahoo&cm_ven=YAHOO
Wed 11:20
TheOptimist.
Jim Crammers Lighting Round.
437.75
No Opinion

Perhaps some one could post the link.Unable to do it myself at present.
Wed 11:10
TheOptimist.
Seeking Alpha
438.00
No Opinion

Check out Jim Crammers "Lighting Round" re GWPH.yesterday,he really rates this share.
Wed 07:58
kingskin
RE: ireland to legalise sativex
438.00
No Opinion

:) faxed chocolate tastes so yummy ! 750 - end of year....(really going out on a limb)
Wed 07:53
kingskin
RE: ireland to legalise sativex
438.00
No Opinion

:) 750 - end of year....

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Gw Pharmaceuticals (GWP) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Gw Pharmaceuticals Plc Ord 0.1P home pageWebsite: Gw Pharmaceuticals Plc Ord 0.1P
Website Description: GW Pharmaceutical



Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.